Skip to main content

Table 3 Incremental cost-effectiveness ratios for VRE screening and isolation program in various scenarios

From: Vancomycin-resistant enterococci (VRE) screening and isolation in the general medicine ward: a cost-effectiveness analysis

Scenario Incremental Cost Incremental QALYs ICER ($/QALY) Probability of CE (at $7500/QALY) Probability of CE (at $50,000/QALY)
VRE Prevalence in-hospital, 10x (outbreak) 122.79 0.0525 2340 0.545 0.556a
Room costs excluded ($0) 20.58 0.0077 2682 0.506 0.508a
Number of beds in ward [33] 109.78 0.0093 11,812 0.505 0.518a
Program length (5000 admissions) 113.05 0.0023 50,094 0.457 0.499a
Isolation, decreased effectiveness (0.75) 99.52 0.0002 510,676 0.458 0.476a
Time horizon, 1 year 109.61 0.0001 856,297 0 0.259
Universal screening VRE screening and isolation 151.44 −0.0039 Dominated 0.484 0.500a
VRE Prevalence in-hospital, 0.5x 108.41 −0.0112 Dominated 0.479 0.501a
  1. aSignifies asymptote at that probability at $50,000/QALY
  2. CE cost-effectiveness, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, VRE vancomycin-resistant enterococci